Designing Biosimilar Studies: Global Regulatory Expectations and Practical Considerations

The biosimilar industry is entering a transformative era. As numerous biologic products approach patent expiration over the next decade, pharmaceutical companies are increasingly focused on developing high-quality biosimilars that can meet growing market demand. However, success in biosimilar development depends on more than analytical similarity alone. Regulatory agencies worldwide expect a robust clinical comparability program capable of demonstrating that a biosimilar has no clinically meaningful differences from its reference product.

For organizations such as Renastra Education, understanding global biosimilar study requirements is essential for supporting professionals, researchers, and organizations involved in clinical development. Designing studies that align with international regulatory expectations requires careful consideration of study design, population selection, dose strategy, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints, safety monitoring, and immunogenicity assessment.

Global Regulatory Framework for Biosimilar Development

Unlike conventional generic medicines, biologics are complex molecules produced through living systems. Because of this complexity, biosimilar development follows a stepwise approach that includes analytical characterization, non-clinical evaluation, and clinical comparability studies.

Major regulatory authorities, including the FDA, EMA, WHO, Health Canada, PMDA, NMPA, MFDS, and CDSCO, generally share the same objective: demonstrating biosimilarity through the totality of evidence. While their expectations largely align, subtle differences exist regarding study design, patient selection, endpoint justification, and comparative efficacy requirements.

A common principle across all agencies is that biosimilar studies should be designed to maximize the ability to detect meaningful differences between the proposed biosimilar and the reference product.

Selecting the Appropriate Reference Product

Choosing the correct reference product is one of the first critical decisions in biosimilar development. Most regulatory agencies require the use of a licensed reference biologic approved within their jurisdiction. Several authorities explicitly prohibit the use of another biosimilar as the reference product.

Beyond regulatory compliance, developers must also consider global development strategies, product sourcing, and the potential need for bridging studies. Proper planning at this stage can significantly reduce development timelines and regulatory complexity.

Optimizing Study Design

Study design should provide the highest sensitivity for detecting differences between products.

Single-dose crossover studies are generally preferred for biologics with short half-lives and low immunogenicity risk because they reduce variability and improve statistical efficiency. However, many biologics possess long half-lives or may induce immune responses that make crossover studies less appropriate.

In such cases, parallel-group studies are often recommended to avoid carryover effects and immunogenicity-related complications. Multiple-dose studies may also be required when single-dose evaluations do not adequately characterize the PK-PD relationship.

The ultimate goal is to balance scientific sensitivity, patient safety, operational feasibility, and regulatory expectations.

Choosing the Most Sensitive Study Population

Regulatory authorities consistently recommend selecting a population capable of detecting subtle differences between the biosimilar and reference product.

Healthy volunteers are often preferred because they typically present less variability than patient populations. Disease-related factors can influence drug disposition, immune responses, and pharmacodynamic outcomes, potentially masking product-related differences.

However, certain biologics may require studies in patients due to safety considerations, disease-specific biomarkers, or elevated immunogenicity risks. When multiple indications exist, regulators generally recommend selecting the patient population that provides the greatest sensitivity for comparative assessment.

Dose Selection Strategy

Dose selection is another critical component of biosimilar study design.

Many biologics exhibit non-linear pharmacokinetics, receptor saturation, or target-mediated drug disposition. As a result, regulators often recommend selecting doses that maximize sensitivity rather than simply reflecting therapeutic use.

Doses positioned on the steep portion of the exposure-response curve may reveal differences more effectively than doses where receptor saturation has already occurred. Nonetheless, scientific justification remains essential regardless of the selected dosing strategy.

Route of Administration Considerations

When a reference biologic is approved through multiple administration routes, regulators generally prefer routes that offer greater sensitivity for detecting differences.

Subcutaneous administration is often favored because it introduces an absorption phase that can reveal differences in product behavior, bioavailability, and local tolerability. Intravenous evaluations may be waived under certain circumstances when sufficient evidence supports comparable absorption and elimination characteristics.

Scientific rationale remains essential whenever alternative routes or waivers are proposed.

Pharmacokinetic and Pharmacodynamic Evaluation

PK studies remain the cornerstone of clinical biosimilarity assessment. Parameters such as AUC and Cmax are widely accepted as primary endpoints because they measure the extent and rate of systemic exposure.

PD biomarkers can provide valuable complementary evidence when they are directly linked to the biologic’s mechanism of action. Effective biomarkers should be sensitive, reproducible, clinically relevant, and capable of detecting meaningful differences between products.

Regulatory agencies increasingly encourage integrated PK/PD studies because they provide a more comprehensive understanding of comparative pharmacology while potentially reducing the need for large comparative efficacy trials.

Comparative Efficacy Studies and Regulatory Evolution

One of the most significant developments in biosimilar regulation has been the reduced reliance on large comparative efficacy studies.

Advances in analytical characterization, combined with sensitive PK/PD methodologies, have enabled regulators to place greater emphasis on the totality of evidence. In many cases, robust analytical and clinical pharmacology data may sufficiently address residual uncertainty without requiring extensive efficacy trials.

This evolving regulatory landscape offers opportunities to streamline development programs while maintaining rigorous scientific standards.

Biosimilarity Assessment Criteria

Most global regulatory agencies continue to accept the traditional equivalence range of 80.00% to 125.00% for primary PK endpoints.

However, biosimilarity extends beyond statistical equivalence alone. Regulators evaluate all available evidence, including analytical similarity, PK comparability, PD responses, safety findings, and immunogenicity profiles.

A successful biosimilar program therefore requires a holistic assessment rather than reliance on any single study outcome.

Safety and Immunogenicity

Safety and immunogenicity remain essential components of biosimilar development.

Even minor manufacturing or formulation differences can influence immune responses, potentially affecting drug exposure, efficacy, or safety. Regulatory agencies require comprehensive comparative assessments of adverse events, anti-drug antibodies, neutralizing antibodies, and their potential impact on clinical outcomes.

Modern biosimilar programs integrate immunogenicity assessment directly into PK, PD, and safety studies, providing a more complete understanding of product comparability.

Conclusion

As biosimilar development continues to expand globally, designing studies that satisfy diverse regulatory expectations has become increasingly important. Success depends on selecting sensitive study populations, optimizing study design, choosing scientifically justified endpoints, and integrating PK, PD, safety, and immunogenicity assessments into a comprehensive development strategy.

At Renastra Education, we believe that a strong understanding of global biosimilar regulations empowers professionals and organizations to navigate complex development pathways more effectively. By applying scientific rigor and regulatory insight, biosimilar developers can build efficient programs that support successful approvals and improve patient access to biologic therapies worldwide.